Renaissance Technologies
PACB icon

Renaissance Technologies’s Pacific Biosciences PACB Stock Holding History

Renaissance Technologies’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62M Sell
966,200
-1,522,900
-61% -$2.21M ﹤0.01% 2085
2026
Q1 		$3.29M Sell
2,489,100
-1,361,500
-35% -$2.44M 0.01% 1614
2025
Q4 		$7.2M Buy
+3,850,600
New +$7.4M 0.01% 1089
2023
Q4 		– Sell
-326,622
Closed -$2.73M – 4024
2023
Q3 		$2.73M Buy
+326,622
New +$3.73M ﹤0.01% 1683
2022
Q3 		– Sell
-114,200
Closed -$505K – 4322
2022
Q2 		$505K Sell
114,200
-754,500
-87% -$4.58M ﹤0.01% 3162
2022
Q1 		$7.91M Buy
+868,700
New +$10M 0.01% 1281
2021
Q4 		– Sell
-273,800
Closed -$7M – 4140
2021
Q3 		$7M Sell
273,800
-547,000
-67% -$16.2M 0.01% 1252
2021
Q2 		$28.7M Buy
820,800
+37,300
+5% +$1.08M 0.04% 554
2021
Q1 		$26.1M Buy
+783,500
New +$27.4M 0.03% 633
2018
Q1 		– Sell
-113,900
Closed -$301K – 3518
2017
Q4 		$301K Buy
+113,900
New +$399K ﹤0.01% 3024
2016
Q4 		– Sell
-374,900
Closed -$3.36M – 3395
2016
Q3 		$3.36M Sell
374,900
-29,164
-7% -$244K 0.01% 1870
2016
Q2 		$2.84M Sell
404,064
-784,636
-66% -$7.17M 0.01% 1978
2016
Q1 		$10.1M Sell
1,188,700
-397,700
-25% -$3.91M 0.02% 1130
2015
Q4 		$20.8M Buy
+1,586,400
New +$14.2M 0.05% 526
2015
Q3 		– Sell
-309,500
Closed -$1.78M – 3308
2015
Q2 		$1.78M Buy
309,500
+184,300
+147% +$1.07M ﹤0.01% 2136
2015
Q1 		$731K Sell
125,200
-12,772
-9% -$88.1K ﹤0.01% 2460
2014
Q4 		$1.08M Buy
+137,972
New +$883K ﹤0.01% 2094
2014
Q2 		– Sell
-105,766
Closed -$566K – 2916
2014
Q1 		$566K Buy
+105,766
New +$669K ﹤0.01% 2310
2013
Q4 		– Sell
-280,100
Closed -$1.55M – 2981
2013
Q3 		$1.55M Buy
280,100
+4,100
+1% +$14.2K ﹤0.01% 1799
2013
Q2 		$698K Buy
+276,000
New +$687K ﹤0.01% 2099

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies's PACB Position: Q2 2026 in Review

Renaissance Technologies reduced its Pacific Biosciences (PACB) stake by 61% in Q2 2026, selling an estimated $2.21M and leaving 966,200 shares worth $1.62M. The position accounts for ﹤0.01% of the portfolio, ranked #2085.

Renaissance Technologies first reported a position in PACB in Q2 2013 and has held it in 20 quarters since. The position peaked at $28.7M in Q2 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Renaissance Technologies held 966,200 shares of Pacific Biosciences worth $1.62M as of Q2 2026.
  • Renaissance Technologies sold 1,522,900 Pacific Biosciences shares in Q2 2026, an estimated $2.21M.
  • Pacific Biosciences made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2085 holding.
  • Renaissance Technologies first reported a position in Pacific Biosciences in Q2 2013 and has held it in 20 quarters since.
  • Renaissance Technologies's Pacific Biosciences position peaked at $28.7M in Q2 2021.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.